149 related articles for article (PubMed ID: 28323868)
1. "Waiting for DAAs": A retrospective chart review of patients with untreated hepatitis C in Rwanda.
Gupta N; Kabahizi J; Mukabatsinda C; Walker TD; Musabeyezu E; Kiromera A; Van Nuil JI; Steiner K; Mukherjee J; Nsanzimana S; Mbituyumuremyi A
PLoS One; 2017; 12(3):e0174148. PubMed ID: 28323868
[TBL] [Abstract][Full Text] [Related]
2. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
Gupta N; Manirambona L; Shumbusho F; Kabihizi J; Murangwa A; Serumondo J; Makuza JD; Nsanzimana S; Muvunyi CM; Mukabatsinda C; Musabeyezu E; Camus G; Grant PM; Kateera F
Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):542-551. PubMed ID: 35248212
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial.
Kateera F; Shumbusho F; Manirambona L; Kabihizi J; Murangwa A; Serumondo J; Makuza JD; Nsanzimana S; Muvunyi CM; Kabakambira JD; Sylvain H; Camus G; Grant PM; Gupta N
Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):533-541. PubMed ID: 35248213
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Hepatitis C Genotypes 1 to 5 in Sub-Saharan Africa Using Direct-Acting Antivirals.
Sultan A; Bane A; Braimoh G; Debes JD
Am J Trop Med Hyg; 2020 Nov; 103(5):2083-2084. PubMed ID: 32828136
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.
Gupta N; Mbituyumuremyi A; Kabahizi J; Ntaganda F; Muvunyi CM; Shumbusho F; Musabeyezu E; Mukabatsinda C; Ntirenganya C; Van Nuil JI; Kateera F; Camus G; Damascene MJ; Nsanzimana S; Mukherjee J; Grant PM
Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):119-126. PubMed ID: 30552056
[TBL] [Abstract][Full Text] [Related]
7. Time to complete hepatitis C cascade of care among patients identified during mass screening campaigns in rural Rwanda: a retrospective cohort study.
Kamali I; Shumbusho F; Barnhart DA; Nyirahabihirwe F; Gakuru JP; Dusingizimana W; Nizeyumuremyi E; Habinshuti P; Walker S; Makuza JD; Serumondo J; Nshogoza Rwibasira G; Ndahimana JD
BMC Infect Dis; 2022 Mar; 22(1):272. PubMed ID: 35313817
[TBL] [Abstract][Full Text] [Related]
8. Achieving a high cure rate with direct-acting antivirals for chronic Hepatitis C virus infection in Cameroon: a multi-clinic demonstration project.
Coyer L; Njoya O; Njouom R; Mossus T; Kowo MP; Essomba F; Boers A; Coutinho R; Ondoa P;
Trop Med Int Health; 2020 Sep; 25(9):1098-1109. PubMed ID: 32502290
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
[TBL] [Abstract][Full Text] [Related]
11. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.
Spradling PR; Xing J; Rupp LB; Moorman AC; Gordon SC; Lu M; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Holmberg SD;
J Clin Gastroenterol; 2018 Aug; 52(7):641-647. PubMed ID: 28590325
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Direct-acting Antivirals for the Treatment of Chronic Hepatitis C in Rwanda: A Retrospective Study.
Nsanzimana S; Penkunas MJ; Liu CY; Sebuhoro D; Ngwije A; Remera E; Umutesi J; Ntirenganya C; Mugeni SD; Serumondo J
Clin Infect Dis; 2021 Nov; 73(9):e3300-e3307. PubMed ID: 32505127
[TBL] [Abstract][Full Text] [Related]
13. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.
Lin M; Kramer J; White D; Cao Y; Tavakoli-Tabasi S; Madu S; Smith D; Asch SM; El-Serag HB; Kanwal F
Aliment Pharmacol Ther; 2017 Nov; 46(10):992-1000. PubMed ID: 28949020
[TBL] [Abstract][Full Text] [Related]
14. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M
Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda.
Riedel DJ; Taylor S; Simango R; Kiromera A; Sebeza J; Baribwira C; Musabeyezu E
Trans R Soc Trop Med Hyg; 2016 Aug; 110(8):495-7. PubMed ID: 27618922
[TBL] [Abstract][Full Text] [Related]
16. HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study.
Bailey H; Nizova N; Martsynovska V; Volokha A; Malyuta R; Cortina-Borja M; Thorne C;
BMC Infect Dis; 2016 Dec; 16(1):755. PubMed ID: 27955711
[TBL] [Abstract][Full Text] [Related]
17. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
Steininger K; Boyd A; Dupke S; Krznaric I; Carganico A; Munteanu M; Neifer S; Schuetze M; Obermeier M; Arasteh K; Baumgarten A; Ingiliz P
J Viral Hepat; 2017 Oct; 24(10):832-839. PubMed ID: 28439936
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
Lam JO; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ; Marcus JL
Int J STD AIDS; 2019 Jun; 30(7):689-695. PubMed ID: 31046611
[TBL] [Abstract][Full Text] [Related]
19. The Cascade of Care for Hepatitis C Treatment in Rwanda: A Retrospective Cohort Study of the 2017-2019 Mass Screening and Treatment Campaign.
Nisingizwe MP; Makuza JD; Janjua NZ; Bansback N; Hedt-Gauthier B; Serumondo J; Remera E; Law MR
Viruses; 2023 Feb; 15(3):. PubMed ID: 36992370
[TBL] [Abstract][Full Text] [Related]
20. Short article: Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: a retrospective study in a large urban tertiary center.
Sims OT; Guo Y; Shoreibah MG; Venkata K; Fitzmorris P; Kommineni V; Romano J; Massoud OI
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1219-1222. PubMed ID: 28857899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
